Press Releases Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2026202520242023202220212020 November 6, 2024 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference October 21, 2024 Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support September 9, 2024 Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations September 9, 2024 Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support September 3, 2024 Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference August 6, 2024 Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update June 24, 2024 Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 21, 2024 Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit May 2, 2024 Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update April 5, 2024 Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing April 5, 2024 Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition April 5, 2024 Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 49 - 60 of 133 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2026202520242023202220212020 November 6, 2024 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference October 21, 2024 Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support September 9, 2024 Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations September 9, 2024 Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support September 3, 2024 Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference August 6, 2024 Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update June 24, 2024 Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 21, 2024 Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit May 2, 2024 Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update April 5, 2024 Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing April 5, 2024 Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition April 5, 2024 Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 49 - 60 of 133
November 6, 2024 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
October 21, 2024 Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
September 9, 2024 Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
September 9, 2024 Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
September 3, 2024 Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 6, 2024 Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
June 24, 2024 Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2024 Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
April 5, 2024 Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
April 5, 2024 Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
